What is non-hodgkin lymphoma?
NHL includes dozens of biologically distinct lymphoid cancers rather than one disease. Examples include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, peripheral T-cell lymphomas, and lymphoplasmacytic lymphoma. They can begin in lymph nodes or extranodal tissues such as the stomach, skin, brain, or spleen. Clinicians often describe a lymphoma as indolent or aggressive, but its formal pathologic subtype is more informative. Some infections, immune deficiencies, autoimmune disorders, prior therapies, and inherited factors increase risk for particular subtypes; most people have no single identifiable cause. Certain indolent lymphomas can transform into a faster-growing form. Because treatments differ widely, expert hematopathology review is valuable when classification is difficult. Repeat tissue review may be important when disease behavior changes unexpectedly. Care depends on subtype, stage, sites and tumor burden, symptoms, cell-surface and molecular biomarkers, treatment history, age, organ function, infection status, and personal goals.
Signs and symptoms
NHL may present as a painless, persistent enlarged lymph node in the neck, underarm, groin, chest, or abdomen. Unexplained fever, drenching night sweats, and significant weight loss are called B symptoms and can affect prognosis or staging. Other possible features include fatigue, itching, abdominal pain or fullness, chest pressure, cough, shortness of breath, or early satiety. Extranodal lymphoma can cause site-specific symptoms involving the skin, stomach or bowel, brain, testis, bone, or other organs. Marrow involvement may contribute to anemia, infections, easy bruising, or bleeding. Rapidly growing masses or neurologic changes require timely assessment. These findings are not specific to lymphoma and may result from common infections, inflammatory or autoimmune disease, medication effects, or other noncancer conditions.
Diagnosis and staging
An excisional or core biopsy of an involved node or tissue is usually required; fine-needle samples alone may not preserve enough architecture for classification. Pathologists combine cell appearance, immunohistochemistry, flow cytometry, chromosome studies, and molecular tests to establish the WHO/ICC subtype and clinically relevant biomarkers. Evaluation may include a complete blood count, chemistry and lactate dehydrogenase levels, infection testing, and PET-CT or CT. Bone marrow biopsy, lumbar puncture, endoscopy, or organ-specific imaging is used for selected subtypes or sites. Many NHLs use an Ann Arbor or Lugano stage I–IV framework, but stage has different implications across subtypes. Clinicians also consider bulk, extranodal sites, growth rate, prognostic indices, and whether disease is newly diagnosed, transformed, refractory, or recurrent. Care depends on exact pathology, stage, biomarkers, symptoms, prior treatment, age, and overall health; repeat biopsy may be needed if behavior changes.
Established treatment paths
Treatment is subtype-specific. Some asymptomatic indolent B-cell lymphomas can be monitored until clear indications for therapy develop. Localized indolent disease may be treated with involved-site radiation. Systemic treatment can include an anti-CD20 monoclonal antibody alone or combined with chemotherapy, immunomodulatory therapy, or targeted agents. Aggressive B-cell lymphomas often require prompt curative-intent immunochemotherapy, sometimes followed by radiation to selected sites. T-cell, natural killer cell, central nervous system, cutaneous, and infection-associated lymphomas use distinct regimens. Targeted options may inhibit BTK, BCL2, EZH2, or other pathways when appropriate; antibody–drug conjugates, bispecific antibodies, and CAR T-cell therapies have roles in selected relapsed or refractory B-cell lymphomas. Stem cell transplantation may be considered for certain responsive relapses. Surgery is mainly diagnostic, though it has limited subtype-specific roles. The plan depends on pathology, stage, tumor burden, biomarkers, organ involvement, prior response, age, comorbidities, and preferences. Clinical trials are particularly relevant for uncommon subtypes or disease that returns. Response is assessed serially over time with subtype-appropriate examinations, laboratory tests, and imaging, often including PET-CT for avid lymphomas.
Supportive care
Supportive care may include infection prevention and treatment, vaccination planning, blood-count support, nausea control, pain management, nutrition, activity, and mental health care. Teams may assess tumor lysis risk before therapy and monitor heart, nerve, kidney, liver, or immune effects according to the regimen. Fertility preservation can be discussed before treatment. Palliative care supports symptom relief and quality of life alongside active lymphoma therapy. People with splenic dysfunction or prior splenectomy need specific infection precautions. Some treatments reactivate hepatitis B or other infections, so screening and preventive medicines may be needed. Follow-up is tailored to subtype and treatment; new symptoms often guide imaging. Supplements, vaccines, and medicines should be reviewed for interactions and immune effects.
Profiles documenting non-hodgkin lymphoma care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-09-29. The links below identify the public and clinic-provided materials used for this page.
- NCI: Non-Hodgkin Lymphoma Treatment ↗Checked 2026-09-29
- NCI: Lymphoma—Patient Version ↗Checked 2026-09-29
How Cancer Clinic Finder compiles information · Suggest a factual correction
